LIM
TPST icon

Longfellow Investment Management’s Tempest Therapeutics TPST Stock Holding History

Longfellow Investment Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-7
Closed -$364K – 54
2014
Q3 		$364K Buy
+7
New +$245K 0.09% 41

Other funds holding TPST

LF
Longwood Fund Boston, Massachusetts $125M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return

Longfellow Investment Management's TPST Position: Q4 2014 in Review

Longfellow Investment Management sold out of Tempest Therapeutics (TPST) in Q4 2014, closing a stake of 7 shares — an estimated $364K sold.

Longfellow Investment Management first reported a position in TPST in Q3 2014 and held it in 1 quarter. The position peaked at $364K in Q3 2014. 73 funds tracked by Wall St. Rank hold TPST as of Q4 2014.

  • Longfellow Investment Management reported no remaining Tempest Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Longfellow Investment Management sold 7 Tempest Therapeutics shares in Q4 2014, an estimated $364K.
  • Longfellow Investment Management first reported a position in Tempest Therapeutics in Q3 2014 and held it in 1 quarter.
  • Longfellow Investment Management's Tempest Therapeutics position peaked at $364K in Q3 2014.
  • 73 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2014.

Based on Longfellow Investment Management's 13F filing for Q4 2014, filed 4 Feb 2015.